Unternehmen in FRIEDRICHSDORF

PHARMALEX GMBH

BeobachtenFeed abonnierenFörderungen als CSV

In 0 Bekanntmachungen genannt, seit 1. Januar 2018, aber in keiner als Auftragnehmer eines Zuschlags.

Fördermittel

Kohesio und Finanztransparenzsystem der EU, so gezählt.

5 Förderungen, zusammen 1,7 Mio. €.

QuelleBetragFörderungen
EU-Haushalt (Finanztransparenzsystem)1,7 Mio. €55
JahrProgrammProjektBetrag und Beleg
2023EU Budget - European CommissionHADEA - European Health and Digital Executive Agency101057777 - INSPIRE - DEVELOPING NOVEL INHALED BIOENGINEERED EXTRACELLULAR VESICLE RNA BASED ADVANCED THERAPEUTICS, DELIVERED BY TAILORED AEROSOL DELIVERY TECHNOLOGY FOR THE TREATMENT OF LUNG CANCER101057777 - INSPIRE - DEVELOPING NOVEL INHALED BIOENGINEERED EXTRACELLULAR VESICLE RNA BASED ADVANCED THERAPEUTICS, DELIVERED BY TAILORED AEROSOL DELIVERY TECHNOLOGY FOR THE TREATMENT OF LUNG CANCER36.146 €Mittelbindung
2022EU Budget - European CommissionHADEA - European Health and Digital Executive Agency101057777 - INSPIRE - DEVELOPING NOVEL INHALED BIOENGINEERED EXTRACELLULAR VESICLE RNA BASED ADVANCED THERAPEUTICS, DELIVERED BY TAILORED AEROSOL DELIVERY TECHNOLOGY FOR THE TREATMENT OF LUNG CANCER101057777 - INSPIRE - DEVELOPING NOVEL INHALED BIOENGINEERED EXTRACELLULAR VESICLE RNA BASED ADVANCED THERAPEUTICS, DELIVERED BY TAILORED AEROSOL DELIVERY TECHNOLOGY FOR THE TREATMENT OF LUNG CANCER707.813 €Mittelbindung
2022EU Budget - European CommissionHADEA - European Health and Digital Executive Agency101057777 - INSPIRE - DEVELOPING NOVEL INHALED BIOENGINEERED EXTRACELLULAR VESICLE RNA BASED ADVANCED THERAPEUTICS, DELIVERED BY TAILORED AEROSOL DELIVERY TECHNOLOGY FOR THE TREATMENT OF LUNG CANCER101057777 - INSPIRE - DEVELOPING NOVEL INHALED BIOENGINEERED EXTRACELLULAR VESICLE RNA BASED ADVANCED THERAPEUTICS, DELIVERED BY TAILORED AEROSOL DELIVERY TECHNOLOGY FOR THE TREATMENT OF LUNG CANCER188.750 €Mittelbindung
2022EU Budget - European CommissionHADEA - European Health and Digital Executive Agency101057777 - INSPIRE - DEVELOPING NOVEL INHALED BIOENGINEERED EXTRACELLULAR VESICLE RNA BASED ADVANCED THERAPEUTICS, DELIVERED BY TAILORED AEROSOL DELIVERY TECHNOLOGY FOR THE TREATMENT OF LUNG CANCER101057777 - INSPIRE - DEVELOPING NOVEL INHALED BIOENGINEERED EXTRACELLULAR VESICLE RNA BASED ADVANCED THERAPEUTICS, DELIVERED BY TAILORED AEROSOL DELIVERY TECHNOLOGY FOR THE TREATMENT OF LUNG CANCER47.188 €Mittelbindung
2018EU Budget - European CommissionRTD - Directorate-General for Research and Innovation825925 - IPSPINE - INDUCED PLURIPOTENT STEM CELL-BASED THERAPY FOR SPINAL REGENERATION825925 - IPSPINE - INDUCED PLURIPOTENT STEM CELL-BASED THERAPY FOR SPINAL REGENERATION676.377 €Mittelbindung

Angaben aus den Bekanntmachungen

0 Nennungen seit 1. Januar 2018, zuletzt am 1. Januar 2018, dieser Organisation zugeordnet. Wie wir zuordnen

Anschrift
BAHNSTRASSE 42-46, 61381 FRIEDRICHSDORF
Registernummer (EUID)
DEM1202.HRB13017
USt-IdNr.
DE295381486
Schreibweisen
  • PHARMALEX GMBH